No teratogenic effect of prenoxdiazine: A population-based case-control study

Zoltan Bártfai, Akos Somoskövi, E. Puhó, E. Czeizel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The objective of this study was to investigate the human teratogenic potential of oral prenoxdiazine treatment during pregnancy. The analysis of cases with congenital abnormalities and their matched controls without congenital abnormalities was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of the 22 843 pregnant women who had offspring with congenital abnormalities, 158 (0.7%) were treated with prenoxdiazine. Of the 38 151 pregnant women who had babies without any defects in the study period (control group), 226 (0.6%) were treated with prenoxdiazine (adjusted prevalence odds ratio, 1.0; 95% confidence interval, 0.8-1.3). The comparison of cases and their matched controls did not show a significantly higher rate of prenoxdiazine treatment during the second and third months of gestation in the total (adjusted prevalence odds ratio, 1.4; 95% confidence interval, 0.9-2.2) or in any group of congenital abnormalities. Treatment with prenoxdiazine during pregnancy did not have any teratogenic risk to the fetus. Thus, prenoxdiazine treatment in pregnant women with an unproductive cough may be beneficial.

Original languageEnglish
Pages (from-to)16-21
Number of pages6
JournalCongenital Anomalies
Volume47
Issue number1
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Case-Control Studies
Population
Pregnant Women
Pregnancy
Odds Ratio
Confidence Intervals
Therapeutics
Cough
libexin
Fetus
Control Groups

Keywords

  • Case-control study
  • Congenital abnormality
  • Pregnancy
  • Prenoxdiazine

ASJC Scopus subject areas

  • Developmental Biology

Cite this

No teratogenic effect of prenoxdiazine : A population-based case-control study. / Bártfai, Zoltan; Somoskövi, Akos; Puhó, E.; Czeizel, E.

In: Congenital Anomalies, Vol. 47, No. 1, 03.2007, p. 16-21.

Research output: Contribution to journalArticle

@article{6fba26fbf6be4d1f934fff80a3689256,
title = "No teratogenic effect of prenoxdiazine: A population-based case-control study",
abstract = "The objective of this study was to investigate the human teratogenic potential of oral prenoxdiazine treatment during pregnancy. The analysis of cases with congenital abnormalities and their matched controls without congenital abnormalities was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of the 22 843 pregnant women who had offspring with congenital abnormalities, 158 (0.7{\%}) were treated with prenoxdiazine. Of the 38 151 pregnant women who had babies without any defects in the study period (control group), 226 (0.6{\%}) were treated with prenoxdiazine (adjusted prevalence odds ratio, 1.0; 95{\%} confidence interval, 0.8-1.3). The comparison of cases and their matched controls did not show a significantly higher rate of prenoxdiazine treatment during the second and third months of gestation in the total (adjusted prevalence odds ratio, 1.4; 95{\%} confidence interval, 0.9-2.2) or in any group of congenital abnormalities. Treatment with prenoxdiazine during pregnancy did not have any teratogenic risk to the fetus. Thus, prenoxdiazine treatment in pregnant women with an unproductive cough may be beneficial.",
keywords = "Case-control study, Congenital abnormality, Pregnancy, Prenoxdiazine",
author = "Zoltan B{\'a}rtfai and Akos Somosk{\"o}vi and E. Puh{\'o} and E. Czeizel",
year = "2007",
month = "3",
doi = "10.1111/j.1741-4520.2006.00136.x",
language = "English",
volume = "47",
pages = "16--21",
journal = "Congenital Anomalies",
issn = "0914-3505",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - No teratogenic effect of prenoxdiazine

T2 - A population-based case-control study

AU - Bártfai, Zoltan

AU - Somoskövi, Akos

AU - Puhó, E.

AU - Czeizel, E.

PY - 2007/3

Y1 - 2007/3

N2 - The objective of this study was to investigate the human teratogenic potential of oral prenoxdiazine treatment during pregnancy. The analysis of cases with congenital abnormalities and their matched controls without congenital abnormalities was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of the 22 843 pregnant women who had offspring with congenital abnormalities, 158 (0.7%) were treated with prenoxdiazine. Of the 38 151 pregnant women who had babies without any defects in the study period (control group), 226 (0.6%) were treated with prenoxdiazine (adjusted prevalence odds ratio, 1.0; 95% confidence interval, 0.8-1.3). The comparison of cases and their matched controls did not show a significantly higher rate of prenoxdiazine treatment during the second and third months of gestation in the total (adjusted prevalence odds ratio, 1.4; 95% confidence interval, 0.9-2.2) or in any group of congenital abnormalities. Treatment with prenoxdiazine during pregnancy did not have any teratogenic risk to the fetus. Thus, prenoxdiazine treatment in pregnant women with an unproductive cough may be beneficial.

AB - The objective of this study was to investigate the human teratogenic potential of oral prenoxdiazine treatment during pregnancy. The analysis of cases with congenital abnormalities and their matched controls without congenital abnormalities was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of the 22 843 pregnant women who had offspring with congenital abnormalities, 158 (0.7%) were treated with prenoxdiazine. Of the 38 151 pregnant women who had babies without any defects in the study period (control group), 226 (0.6%) were treated with prenoxdiazine (adjusted prevalence odds ratio, 1.0; 95% confidence interval, 0.8-1.3). The comparison of cases and their matched controls did not show a significantly higher rate of prenoxdiazine treatment during the second and third months of gestation in the total (adjusted prevalence odds ratio, 1.4; 95% confidence interval, 0.9-2.2) or in any group of congenital abnormalities. Treatment with prenoxdiazine during pregnancy did not have any teratogenic risk to the fetus. Thus, prenoxdiazine treatment in pregnant women with an unproductive cough may be beneficial.

KW - Case-control study

KW - Congenital abnormality

KW - Pregnancy

KW - Prenoxdiazine

UR - http://www.scopus.com/inward/record.url?scp=33846784085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846784085&partnerID=8YFLogxK

U2 - 10.1111/j.1741-4520.2006.00136.x

DO - 10.1111/j.1741-4520.2006.00136.x

M3 - Article

C2 - 17300686

AN - SCOPUS:33846784085

VL - 47

SP - 16

EP - 21

JO - Congenital Anomalies

JF - Congenital Anomalies

SN - 0914-3505

IS - 1

ER -